Viridian Therapeutics, Inc. (VRDN) Earnings Call Transcript & Summary

Hello, everyone. Welcome to the Viridian Therapeutics, Inc. 2021 Annual Meeting of Stockholders. I will now pass the call to Jonathan Violin.

Good morning. I'm Jonathan Violin, and I'm the President, Chief Executive Officer and a Director of Viridian Therapeutics. I'm very happy to welcome you to the Viridian Therapeutics 2021 Annual Stockholders' meeting. Since the meeting is being held virtually via live webcast, we have stockholders attending via web portal. Before I call the meeting to order, I'd like to introduce you to the members of the Board and the business team who are with us today. The other members of the Board are Jeff Hatfield, Chair President of our Board; Peter Harwin, Tomas Kiselak, Arlene Morris and Joseph Turner. Mr. Hatfield and Mr. Turner will not be standing for reelection at today's annual meeting, and we'd like to take this opportunity to thank them for their service to the company. The other members of our business team here today are Lara Meisner, our Vice President of Legal; and Barrett Katz, our Chief Medical Officer. I'd also like to introduce Erika Whitmore and Chau Ta of KPMG, the company's auditors; and Melanie Gertz of Gibson, Dunn & Crutcher, the company's legal counsel, who are available to respond to appropriate questions. The meeting will now officially come to order. We will proceed with the formal business of the meeting as set forth in your notice of the annual meeting and proxy statement. After the formal part of our meeting, we'll give you an opportunity to ask any questions you may have. Please note that this meeting is being recorded. Will the secretary of the meeting please report at this time with respect to the mailing of the notice of the meeting and the stockholders' list?

I have at this meeting a complete list of the stockholders of record of the company's common stock on April 15, 2021, the record date for this meeting. I also have an affidavit certifying that on April 30, 2021, a notice of the Annual Meeting of Stockholders of the company was deposited in the United States Mail to all stockholders of record at the close of business on April 30, 2021.

At this time, I'd like to introduce Elsie Fletcher-Rosenthal, a representative of Broadridge Financial Solutions. I'm appointing Ms. Fletcher-Rosenthal to act as inspector of election at this meeting. Ms. Fletcher-Rosenthal has taken and subscribed the customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. Her function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Will the Secretary please report at this time with respect to the existence of a quorum?

I have been informed by the inspector of election that proxies have been received for 5,822,428 of the 7,231,370 shares of common stock outstanding on the record date, which represents approximately 80.51% of the total number of outstanding shares. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting. If you have not yet delivered your proxy or wish to change your vote, you may do so by clicking on the button marked Vote Here and following the instructions.

We'll now proceed with the formal business of this meeting. There are 3 proposals to be considered by the stockholders at this meeting. Please note that after all the proposals have been presented, we will give stockholders an opportunity to ask questions by entering your question in the text box on your web portal screen. Please also include your name and e-mail address with your questions. The time is now 12:05 p.m. Eastern Time on Thursday, June 3, 2021, and the polls are now open for voting on all matters to be presented. The polls will be closed to voting after we go through the matters to be voted on. The first item of business is the election of 4 director nominees to serve until the next annual meeting and until their successors are duly elected and qualified or each to serve for staggered terms ending at the 2022, 2023 and 2024 annual meetings if Proposal 4 is approved. The nominees for Director are Jonathan Violin, Peter Harwin, Tomas Kiselak and Arlene Morris. You can find information for each of these nominees regarding their background and qualifications to serve as Director in the proxy statement. The second item of business today is the ratification of the selection by the Audit Committee of the Board of Directors of KPMG as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2021. The appointment of KPMG is also discussed in the proxy statement. The third item of business today is the advisory vote on the executive compensation of the company's named executive officers as described in the proxy statement. The stockholders have been asked to vote on an advisory basis on the following resolution: resolved that the compensation paid to the company's named executive officers as disclosed pursuant [indiscernible] of regulation S-K, including the executive compensation discussion below, compensation tables and narrative discussion is hereby approved. That was the final proposal for today's meeting. The secretary will now describe the voting procedures.

Voting is by proxy and online ballot. You do not need to do anything if you've already sent in your signed proxy, previously voted online or by telephone or if you have submitted your proxy or voted online at this meeting. Any stockholder who hasn't yet voted or wishes to change his or her vote may do so by clicking the button marked Vote Here on the web portal and following the instructions. Each share of common stock is entitled to 1 vote. We'll pause here to make sure that all of the stockholders in attendance have had time to deliver any online votes. [Voting]